Canine Pipeline

KindredBio is pursuing a multi-pronged approach toward atopic dermatitis.

KindredBio reported positive topline results from its pilot field effectiveness study of tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin-31, for the treatment of atopic dermatitis in dogs. Pivotal efficacy study commenced in the fourth quarter of 2020.

KindredBio unveiled positive results in a new long-acting interleukin-31 antibody program (KIND-039) that integrates the Company's novel half-life extension technology in April 2021. Results from the pharmacokinetic study of the molecule demonstrated that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing. KindredBio's half-life extension technology is intended to reduce dosing frequency, lower doses, and/or reduce cost of goods sold, while increasing pet owner convenience and compliance.

We reported positive results from our pilot laboratory study of our interleukin-4R molecule, including evidence of positive efficacy and dose response. The KIND-032 program is proceeding as expected with preparations underway for a pivotal study.

The company reported positive results from its pilot efficacy study of its canine IL-4/13 SINK molecule in the first quarter of 2020. An initial pilot study for IL-17 has also been completed and the molecule was well-tolerated. Both programs are currently on hold pending further funding or partnering capital.